The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Inobrodib is a potential new treatment for people with cancer, and multiple myeloma in particular. It is a small molecule drug that targets p300/CBP, lowering the expression of key cancer drivers, ...

Results show promising early efficacy of 67% patients (ORR) treated at 35mg doses of inobrodib in combination with pomalidomide (pom) and dexamethasone (dex), in relapsed refractory multiple myeloma ...

Proceeds to support registration-enabling trials, DOMMINO-1 and DOMMINO-2, and continued development of the first-in-class p300/CBP inhibitor Financing led by Venrock Healthcare Capital Partners, with ...

CellCentric has developed a first-in-class small molecule inhibitor drug, inobrodib, that targets twin cancer gene regulators, p300 and CBP. An extensive Phase I clinical programme has been undertaken ...

CellCentric secures investment from American Cancer Society’s impact venture capital fund to advance inobrodib, its ground-breaking p300/CBP targeted therapy Inobrodib is the first drug to target p300 ...

– Enrollment underway in UK and U.S. for initial registration-supporting study; first patient dosed at The Royal Marsden NHS Foundation Trust in London – – InoPd with inobrodib 20 mg previously ...

New cohorts initiated in ongoing Phase 1/2 clinical trial to evaluate inobrodib in combination with teclistamab or elranatamab for the treatment of relapsed/refractory multiple myeloma Initial safety ...

Funding to support development of company’s oral p300/CBP inhibitor. CellCentric, a UK-based biotechnology company, have officially announced a major investment from Pfizer, with $25 million allocated ...

[Stay on top of transportation news: Get TTNews in your inbox.] Cellcentric began pilot production of hydrogen fuel cells June 20 at its Esslingen plant in Germany, the joint venture between Daimler ...

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well. CellCentric’s $120 million ...